Core Viewpoint - The company reported a significant decline in revenue and profit for the first half of 2025, primarily due to the inclusion of two products in centralized procurement [1] Financial Performance - Total revenue for the period was 13.273 billion RMB, representing a year-on-year decrease of 18.5% [1] - Profit attributable to shareholders was 2.548 billion RMB, down 15.64% year-on-year [1] - Basic earnings per share were 0.2229 RMB [1] - The company proposed an interim dividend of 0.14 HKD per share, compared to 0.16 HKD in the same period last year [1] Margin Analysis - Gross profit margin decreased by 6.0 percentage points to 65.6% compared to the same period last year [1] - The decline in gross margin was mainly attributed to a reduced proportion of revenue from the prescription drug business [1]
港股异动 | 石药集团(01093)午后一度跌超4% 上半年纯利同比减少15.64% 中期息14港仙